Search Results for "Bacterial Conjunctivitis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Bacterial Conjunctivitis. Results 11 to 20 of 21 total matches.

Azelaic Acid (Finacea) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003  (Issue 1165)
. Ocular involvement such as blepharitis or conjunctivitis is common; keratitis and corneal scarring occur ...
Azelaic acid 15% gel (Finacea Berlex) is now available in the US for treatment of mild to moderate rosacea. A 20% cream formulation of the drug (Azelex Allergan; Medical Letter 1996; 38:52) has been marketed here since 1996 for treatment of acne. The effectiveness of Finacea compared to its own vehicle and to metronidazole gel is discussed. Information on the drug's mechanism of action, adverse effects, dosage and cost are also included.
Med Lett Drugs Ther. 2003 Sep 15;45(1165):76 |  Show IntroductionHide Introduction

Drugs for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
(a bulbous nose), particularly in men. Blepharitis and conjunctivitis are common. Keratitis and corneal ...
Rosacea is a common, chronic inflammatory facial eruption of unknown cause. It is more prevalent in women than in men, and disease onset typically occurs after age 30. Rosacea is characterized by erythema, telangiectasia, and flushing, and sometimes by recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. Some patients develop granulomas and tissue hypertrophy, which may lead to rhinophyma (a bulbous nose), particularly in men. Blepharitis and conjunctivitis are common. Keratitis and corneal scarring occur rarely.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):21-2   doi:10.58347/tml.2024.1695b |  Show IntroductionHide Introduction

Drugs and Vaccines Against Biological Weapons

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2001  (Issue 1115)
, anthrax vaccine is given at 0, 2 and 4 weeks, accompanied throughout by an appropriate antibiotic ...
Concerns have arisen anew about possible use of biological weapons. The pathogens considered most likely to be used for this purpose are discussed in this article. A good source for additional information is www.usamriid.army.mil/education/bluebook.html.
Med Lett Drugs Ther. 2001 Oct 15;43(1115):87-9 |  Show IntroductionHide Introduction

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022  (Issue 1653)
, partners should be examined and tested for STIs, but in most cases partner treatment of bacterial STIs ...
This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
Med Lett Drugs Ther. 2022 Jun 27;64(1653):97-104 |  Show IntroductionHide Introduction

Dermal Fillers

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
of wrinkles and folds. 1 These fillers are often used in conjunction with botulinum toxin type A (Botox ...
Several injectable products are available for soft tissue augmentation of wrinkles and folds. These fillers are often used in conjunction with botulinum toxin type A (Botox) injections.
Med Lett Drugs Ther. 2007 May 7;49(1260):39-40 |  Show IntroductionHide Introduction

Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017  (Issue 1519)
patients who received every-otherweek dupilumab monotherapy in the SOLO studies, conjunctivitis occurred ...
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. It can be used with or without topical corticosteroids.
Med Lett Drugs Ther. 2017 Apr 24;59(1519):64-6 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
to liquid or vapor mustard range from ocular irritation and conjunctivitis to corneal burns and blindness ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
, then 40 mg q2 weeks (40 mg/week may be needed in some patients) ▶ Serious bacterial infections ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
Chronic azithromycin use can lead to antibiotic resistance, hearing loss, and QT-interval prolongation ...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92   doi:10.58347/tml.2024.1716a |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
bacterial infections, histoplasmosis, and reactivation of hepatitis B virus and tuberculosis (TB ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction